文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌剂量递增IMRT的15年结局

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data.
PubMed 文献 · Adv Radiat Oncol · 2019-04-04

报告1996至1998年在本机构接受81 Gy或86.4 Gy剂量递增IMRT的301例局限期前列腺癌患者的15年结局,中位随访11.6年。按NCCN危险分组,低、中、高危组15年无复发生存分别为76%、65%、55%,前列腺癌特异性死亡率分别为1.9%、7.1%、12.2%。晚期3级胃肠毒性1.0%,3级及以上泌尿生殖毒性2.3%。

要点

  • 低、中、高危组15年无复发生存分别为76%、65%、55%。
  • 晚期3级胃肠毒性发生率1.0%,3级及以上泌尿生殖毒性2.3%。
  • 38例(12.6%)发生第二原发恶性肿瘤,其中8例为野内恶性肿瘤。

核心结论

  • 高剂量IMRT治疗局限期前列腺癌耐受性良好,长期3级及以上胃肠与泌尿生殖毒性发生率低,前列腺癌特异性生存良好。

研究设计与样本

  • 单机构回顾性数据库分析,纳入1996至1998年首批接受81 Gy(269例,89%)或86.4 Gy(32例,11%)IMRT的患者共301例。
  • 毒性按CTCAE 3.0版评分,中位随访11.6年(范围5-21年)。
  • 按NCCN危险分组:低危29%、中危49%、高危22%。

主要发现

  • 15年无复发生存:低危76%、中危65%、高危55%。
  • 15年无远处转移生存:低危88%、中危75%、高危63%。
  • 前列腺癌特异性死亡率:低危1.9%、中危7.1%、高危12.2%。
  • 晚期3级胃肠毒性3例(1.0%),无4级胃肠毒性,放疗至晚期3级胃肠毒性中位时间2.9年,1例发生在10年后。
  • 晚期3级和4级泌尿生殖毒性分别为6例(2.0%)和1例(0.3%),放疗至晚期3级及以上泌尿生殖毒性中位时间5.5年,2例发生在10年后。

关键数值与推荐

  • 剂量方案:81 Gy或86.4 Gy,采用IMRT技术。
  • 晚期3级及以上胃肠毒性合计1.0%,晚期3级及以上泌尿生殖毒性合计2.3%。
  • 38例(12.6%)发生第二原发恶性肿瘤,其中8例为野内恶性肿瘤,放疗至全部及野内第二原发肿瘤的中位时间均为10年。

临床怎么用

  • 对局限期前列腺癌行剂量递增IMRT时,可参考本队列的低晚期3级及以上胃肠与泌尿生殖毒性风险。
  • 低、中、高危组15年无复发生存与前列腺癌特异性死亡数据可用于危险分层下的预后沟通。
  • 晚期毒性可在10年后出现,第二原发肿瘤中位出现时间为10年,提示需长期随访。

局限性

  • 为单机构回顾性队列,仅纳入1996至1998年首批患者,样本量301例。
  • 毒性按CTCAE 3.0版评分,未报告与剂量递增相关的对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report 15-year outcomes for dose-escalated intensity modulated radiation therapy (IMRT) for localized prostate cancer (PC) by evaluating biochemical relapse, distant metastases, cancer-specific survival, and long-term toxicity. METHODS AND MATERIALS: A database search was conducted for the first cohort of patients treated at this institution with 81 or 86.4 Gy between 1996 and 1998 using IMRT. Toxicity data were scored according to the Common Terminology Criteria for Adverse Events version 3.0. Median follow-up was 11.6 years (range, 5-21 years). RESULTS: In the study, 301 patients were treated with 81 Gy (n = 269, 89%) or 86.4 Gy (n = 32, 11%). Patients were analyzed by National Comprehensive Cancer Network risk group, with 29% low risk (LR), 49% intermediate risk (IR), and 22% high risk (HR). Late grade 3 gastrointestinal (GI) toxicity was seen in 3 patients (1.0%). No grade 4 GI toxicity events occurred. Median time from radiation therapy to late grade 3 GI toxicity was 2.9 years. One event occurred after 10 years. Late grade 3 and 4 genitourinary (GU) toxicity was seen in 6 (2.0%) and 1 (0.3%) patient, respectively. Median time to late grade 3+ GU toxicity was 5.5 years. Two events occurred after 10 years. In addition, 38 (12.6%) developed second primary malignancies (SPMs), 8 of which were in-field malignancies. Median time from radiation therapy to all SPM and in-field SPM was 10 years. The 15-year relapse-free survival was 76%, 65%, and 55% in the LR, IR, and HR groups, respectively. Distant metastases-free survival was 88%, 75%, and 63% for LR, IR, and HR patients, respectively. PC-specific mortality was 1.9%, 7.1%, and 12.2% for LR, IR, and HR patients. CONCLUSIONS: This report represents the longest follow-up data set to our knowledge of patients treated with high-dose IMRT for PC. Our findings indicate that it is well tolerated with 1.0% and 2.3% incidence of long-term grade 3+ GI and GU toxicity, respectively. The cohort had excellent PC-specific survival.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Weg ES, Pei X, Kollmeier MA, et al. Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data. Adv Radiat Oncol. 2019. PMID: 31360805. doi:10.1016/j.adro.2019.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。